| Editor's Note: The Fierce PM Tracker will not publish on Monday in observance of the Martin Luther King, Jr. Day holiday. We'll be back in your inbox on Tuesday. Have a great weekend! |
Today’s Big NewsJan 12, 2024 |
|
Tuesday, January 23, 2024 | 11am ET / 8am PT Join a cutting-edge conversation on January 23, 2024 with Real Chemistry and Quid as they explore how their partnership has forged a deeper understanding of patient insights. Register now.
|
|
| By Angus Liu As one of the first Big Pharmas to embrace antibody-drug conjugates, Roche plans to bet more on the popular cancer modality, Global Head of Pharma Partnering James Sabry, Ph.D., told Fierce. But biotechs looking for a Roche alliance must first meet an invisible bar. |
|
|
|
By Zoey Becker A group of 24,000 users of Gilead's TDF-based HIV meds argue that the company knowingly shelved a safer HIV med to increase its profits. Now, Gilead will have to prove that a manufacturer can't be held liable for its development timeline of an upgraded product. |
By Conor Hale Described as a virtual microscope, the BrainSee program could be used before a PET scan or biopsies of cerebrospinal fluid, according to the developer Darmiyan. |
By Annalee Armstrong Sometimes, you have to act while the tea is hot. For Roivant CEO Matt Gline, that meant dealing out Telavant to Roche for $7.1 billion last year, even if he wasn’t quite ready to let the vant company go. |
|
Wednesday, January 24, 2024 | 2pm ET / 11am PT Join industry experts to hear how digital collection of patient-reported outcomes (PROs) can lay the foundation for advancing health equity, which methods can ensure that PROs are relevant for diverse populations, and what challenges and opportunities still lie ahead. Register now.
|
|
By Conor Hale First announced in June 2023, Illumina Ventures said the new genomics-focused funding and mentorship initiative would take over from its previous Accelerator program, while still offering new companies technical guidance and DNA analysis hardware through the sequencing giant. |
By Ben Adams Rare disease specialist BioMarin has a new CEO in Genentech’s former chief Alexander Hardy and he appears to be shaking up his commercial team as its lead Jeffrey Ajer will now leave the company by July. |
By Annalee Armstrong The biotech industry has a love-hate relationship with the J.P. Morgan Healthcare Conference in San Francisco. Every year, thousands gather on the Golden Gate City and battle rain, hail, floods, what have you, just to make billion-dollar deals. |
By Nick Paul Taylor Reuters and The Wall Street Journal have punctured investors’ hopes that Novartis will buy Cytokinetics. The Swiss drugmaker has reportedly backed away from the potential deal late in negotiations, deflating the biotech’s share price. |
By Andrea Park ResMed first warned in November that some of the masks used with its CPAP machines contain magnets that could potentially interfere with pacemakers, neurostimulators and other implanted medical devices. |
By Eric Sagonowsky Even as obesity and diabetes heavyweights Eli Lilly and Novo Nordisk command headlines with their global manufacturing expansions, Boehringer Ingelheim is getting in on the action. |
By Kevin Dunleavy A preliminary evaluation by the FDA found no evidence that use of popular diabetes and weight-loss drugs from Novo Nordisk and Eli Lilly can cause suicidal thoughts, the U.S. regulator said. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her. |
|
|---|
|
|
|
Stability and particle formation are key variables across the lifecycle. New instruments that improve measurement are transforming testing and becoming necessary. Download this essential reading now for biopharma companies that want to understand how particle detection is evolving and the value new technologies provide across the lifecycle.
|
|
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperThe road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. Sponsored by: S3 Connected Health |
| |
|
